Payment overview · 2025
General Payments
$607.12
31 reported records · 9 companies
Healthcare provider profile · identity verified
Jodi Lashae Cross
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JAMESTOWN, TN · NPI 1881230712
Verified facts
What the public records show
CMS Open Payments records show Jodi Lashae Cross received $607.12 in general payments during 2025 across 31 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 46.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $282.92 | 46.6% | 19 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $97.59 | 16.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.53 | 14.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.66 | 9.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.53 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.79 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.69 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.73 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.68 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $607.12 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $282.92 | 19 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $97.59 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.53 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.66 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 51 |
| Gabapentin | Gabapentin | 181 | 56 |
| Alprazolam | Alprazolam | 179 | 36 |
| Omeprazole | Omeprazole | 174 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 172 | 47 |
| Lisinopril | Lisinopril | 171 | 59 |
| Metformin Hcl | Metformin Hcl | 170 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 165 | 58 |
| Azithromycin | Azithromycin | 153 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 111 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 30 |
| Potassium Chloride | Potassium Chloride | 107 | 23 |
| Prednisone | Prednisone | 106 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 28 |
| Losartan Potassium | Losartan Potassium | 94 | 24 |
| Trazodone Hcl | Trazodone Hcl | 91 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 32 |
| Buspirone Hcl | Buspirone Hcl | 82 | 23 |
| Tramadol Hcl | Tramadol Hcl | 81 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 16 |
| Furosemide | Furosemide | 71 | 22 |
| Ozempic | Semaglutide | 69 | 19 |
| Ezetimibe | Ezetimibe | 64 | 14 |
| Lovastatin | Lovastatin | 62 | 12 |
| Cefdinir | Cefdinir | 61 | 48 |
| Meloxicam | Meloxicam | 61 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 48 |
| Carvedilol | Carvedilol | 57 | 16 |
| Fluconazole | Fluconazole | 56 | 36 |
| Ibuprofen | Ibuprofen | 56 | 21 |
| Sertraline Hcl | Sertraline Hcl | 55 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 16 |
| Ondansetron Odt | Ondansetron | 53 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 21 |
| Eliquis | Apixaban | 47 | 14 |
| Famotidine | Famotidine | 46 | 14 |
| Methylprednisolone | Methylprednisolone | 46 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 13 |
| Glipizide | Glipizide | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | 20 |
| Clonazepam | Clonazepam | 39 | 15 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Baclofen | Baclofen | 35 | 18 |
| Montelukast Sodium | Montelukast Sodium | 35 | 11 |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Methocarbamol | Methocarbamol | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Simvastatin | Simvastatin | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Cephalexin | Cephalexin | 16 | 14 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 14 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Plaquenil | Hydroxychloroquine Sulfate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $607.12 · 31 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, FARXIGA, Kerendia, Ozempic, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error